NASDAQ:IGMS IGM Biosciences (IGMS) Stock Price, News & Analysis $9.31 -0.94 (-9.17%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$9.18▼$10.4050-Day Range$6.28▼$12.3352-Week Range$3.81▼$17.70Volume119,642 shsAverage Volume301,640 shsMarket Capitalization$549.51 millionP/E RatioN/ADividend YieldN/APrice Target$16.63 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get IGM Biosciences alerts: Email Address IGM Biosciences MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside78.6% Upside$16.63 Price TargetShort InterestBearish27.83% of Float Sold ShortDividend StrengthN/ASustainability-1.08Upright™ Environmental ScoreNews Sentiment0.24Based on 9 Articles This WeekInsider TradingSelling Shares$259,064 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($3.01) to ($3.07) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.06 out of 5 starsMedical Sector164th out of 910 stocksPharmaceutical Preparations Industry65th out of 426 stocks 4.3 Analyst's Opinion Consensus RatingIGM Biosciences has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 4 buy ratings, 4 hold ratings, and no sell ratings.Amount of Analyst CoverageIGM Biosciences has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about IGM Biosciences' stock forecast and price target. Previous Next 0.0 Short Interest Percentage of Shares Shorted27.83% of the float of IGM Biosciences has been sold short.Short Interest Ratio / Days to CoverIGM Biosciences has a short interest ratio ("days to cover") of 16.4, which indicates bearish sentiment.Change versus previous monthShort interest in IGM Biosciences has recently increased by 2.48%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldIGM Biosciences does not currently pay a dividend.Dividend GrowthIGM Biosciences does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreIGM Biosciences has received a 71.95% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for cancer", "Preclinical research services for physical health", and "Clinical research services for infectious diseases" products. See details.Environmental SustainabilityThe Environmental Impact score for IGM Biosciences is -1.08. Previous Next 2.4 News and Social Media Coverage News SentimentIGM Biosciences has a news sentiment score of 0.24. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for IGM Biosciences this week, compared to 2 articles on an average week.Search InterestOnly 4 people have searched for IGMS on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.MarketBeat Follows3 people have added IGM Biosciences to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, IGM Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $259,064.00 in company stock.Percentage Held by Insiders57.00% of the stock of IGM Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions42.79% of the stock of IGM Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about IGM Biosciences' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for IGM Biosciences are expected to decrease in the coming year, from ($3.01) to ($3.07) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of IGM Biosciences is -2.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of IGM Biosciences is -2.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioIGM Biosciences has a P/B Ratio of 4.52. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about IGM Biosciences' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Paradigm PressEx-CIA Advisor: “This is How Kamala will Rig the Election”A former CIA advisor with close ties to the White House… Has just released this shocking expose on Kamala’s plan to stop Trump. Every American needs to prepare now…Click here now and learn how to prepare. About IGM Biosciences Stock (NASDAQ:IGMS)IGM Biosciences, Inc., a clinical-stage biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer and autoimmune and inflammatory diseases. It develops Aplitabart, a Death Receptor 5 Agonist IgM antibody for the treatment of colorectal cancer; imvotamab, a CD20 x CD3 bispecific IgM antibody to treat myositis, as well as for the treatment of systemic lupus erythematosus and rheumatoid arthritis that is Phase Ib clinical trial; and IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of autoimmune diseases. IGM Biosciences, Inc. has a collaboration and license agreement with Genzyme Corporation to generate, develop, manufacture, and commercialize IgM antibodies. The company was formerly known as Palingen, Inc. and changed its name to IGM Biosciences, Inc. in 2010. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California.Read More IGMS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart IGMS Stock News HeadlinesSeptember 7 at 6:23 AM | americanbankingnews.comHC Wainwright Lowers IGM Biosciences (NASDAQ:IGMS) Price Target to $11.00September 7 at 1:19 AM | americanbankingnews.comIGM Biosciences (NASDAQ:IGMS) Stock Price Down 4.4% Following Analyst DowngradeSeptember 7, 2024 | Deal Maker (Ad)The solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase, according to the NY Post. With a sky-high 150% turnover rate, the fast food industry is already grappling with labor issues before taking into account these wage hikes. The industry will need a projected 1 million new workers every year through 2032.September 5 at 11:11 PM | markets.businessinsider.comIGM Biosciences: Hold Rating Affirmed Amid Financial Challenges and Clinical CatalystsSeptember 5 at 1:08 PM | benzinga.comThe Analyst Verdict: IGM Biosciences In The Eyes Of 5 ExpertsAugust 28, 2024 | americanbankingnews.comIGM Biosciences (NASDAQ:IGMS) Price Target Lowered to $24.00 at Truist FinancialAugust 28, 2024 | americanbankingnews.comIGM Biosciences (NASDAQ:IGMS) Price Target Cut to $24.00 by Analysts at Truist FinancialAugust 24, 2024 | markets.businessinsider.comTruist Financial Reaffirms Their Buy Rating on IGM Biosciences (IGMS)September 7, 2024 | Deal Maker (Ad)The solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase, according to the NY Post. With a sky-high 150% turnover rate, the fast food industry is already grappling with labor issues before taking into account these wage hikes. The industry will need a projected 1 million new workers every year through 2032.August 16, 2024 | markets.businessinsider.comIGM Biosciences: Hold Rating with Cautious Outlook Amid Clinical Progress and Financial LossesAugust 16, 2024 | markets.businessinsider.comRBC Capital Keeps Their Buy Rating on IGM Biosciences (IGMS)August 15, 2024 | benzinga.comWhat 4 Analyst Ratings Have To Say About IGM BiosciencesAugust 14, 2024 | finanznachrichten.deIGM Biosciences, Inc.: IGM Biosciences Announces Second Quarter 2024 Financial Results and Provides Corporate UpdateAugust 14, 2024 | globenewswire.comIGM Biosciences Announces Second Quarter 2024 Financial Results and Provides Corporate UpdateAugust 6, 2024 | ca.finance.yahoo.comIGMS Mar 2025 22.500 callAugust 4, 2024 | ca.finance.yahoo.comIGMS Mar 2025 10.000 putJuly 31, 2024 | investing.comIGM Biosciences director Julie Hambleton sells $211,848 in stockMay 29, 2024 | globenewswire.comIGM Biosciences to Present at the Jefferies Healthcare ConferenceSee More Headlines Receive IGMS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for IGM Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/14/2024Today9/07/2024Next Earnings (Estimated)11/11/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:IGMS CUSIPN/A CIK1496323 Webigmbio.com Phone650-965-7873FaxN/AEmployees190Year Founded2010Price Target and Rating Average Stock Price Target$16.63 High Stock Price Target$25.00 Low Stock Price Target$8.00 Potential Upside/Downside+78.6%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($4.31) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-246,420,000.00 Net Margins-7,571.35% Pretax Margin-7,554.79% Return on Equity-119.02% Return on Assets-54.74% Debt Debt-to-Equity RatioN/A Current Ratio7.06 Quick Ratio7.06 Sales & Book Value Annual Sales$2.91 million Price / Sales188.77 Cash FlowN/A Price / Cash FlowN/A Book Value$2.06 per share Price / Book4.52Miscellaneous Outstanding Shares59,024,000Free Float25,380,000Market Cap$549.51 million OptionableOptionable Beta0.19 Social Links 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesMr. Fred M. Schwarzer J.D. (Age 71)CEO, President & Director Comp: $977.66kDr. Bruce A. Keyt Ph.D. (Age 70)Chief Scientific Officer Comp: $692.95kDr. Chris H. Takimoto FACP (Age 65)M.D., Ph.D., Chief Medical Officer Comp: $684.95kMr. Misbah Tahir (Age 48)Chief Financial Officer Comp: $957.6kMr. TS HarigopalSenior Vice President of Group OperationsMr. Steven Weber (Age 48)Senior VP, Corporate Controller & Principal Accounting Officer Mr. Paul C. GraffagninoSenior Vice President of Legal AffairsMs. Suzette Tauber (Age 60)Chief Human Resources Officer Dr. Angus M. Sinclair Ph.D.Senior Vice President of Immuno-OncologyDr. Lisa L. Decker Ph.D. (Age 54)Chief Business Officer Comp: $528.18kMore ExecutivesKey CompetitorsCryoportNASDAQ:CYRXZentalis PharmaceuticalsNASDAQ:ZNTLAurinia PharmaceuticalsNASDAQ:AUPHXencorNASDAQ:XNCRJanux TherapeuticsNASDAQ:JANXView All CompetitorsInsiders & InstitutionsPoint72 Asset Management L.P.Bought 27,246 shares on 8/19/2024Ownership: 0.046%The Manufacturers Life Insurance Company Sold 1,572 shares on 8/15/2024Ownership: 0.117%Susquehanna Fundamental Investments LLCSold 11,703 shares on 8/15/2024Ownership: 0.027%AQR Capital Management LLCBought 12,230 shares on 8/15/2024Ownership: 0.021%Marshall Wace LLPBought 36,491 shares on 8/14/2024Ownership: 0.182%View All Insider TransactionsView All Institutional Transactions IGMS Stock Analysis - Frequently Asked Questions How have IGMS shares performed this year? IGM Biosciences' stock was trading at $8.31 at the beginning of the year. Since then, IGMS shares have increased by 12.0% and is now trading at $9.31. View the best growth stocks for 2024 here. How were IGM Biosciences' earnings last quarter? IGM Biosciences, Inc. (NASDAQ:IGMS) released its earnings results on Wednesday, August, 14th. The company reported ($0.79) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.18 by $0.97. The business had revenue of $1.25 million for the quarter, compared to analyst estimates of $51.75 million. IGM Biosciences had a negative net margin of 7,571.35% and a negative trailing twelve-month return on equity of 119.02%. When did IGM Biosciences IPO? IGM Biosciences (IGMS) raised $125 million in an initial public offering (IPO) on Wednesday, September 18th 2019. The company issued 7,800,000 shares at a price of $15.00-$17.00 per share. Jefferies, Piper Jaffray, Stifel and Guggenheim Securities acted as the underwriters for the IPO. Who are IGM Biosciences' major shareholders? IGM Biosciences' top institutional shareholders include TD Asset Management Inc (0.28%), Renaissance Technologies LLC (0.18%), Marshall Wace LLP (0.18%) and Bruce & Co. Inc. (0.17%). Insiders that own company stock include Bros Advisors Lp Baker, Fred Schwarzer, Bruce Keyt, Misbah Tahir, Jakob Haldor Topsoe, Chris H Takimoto, George Gauthier, Michael D Loberg, Steven Weber and Julie Hambleton. View institutional ownership trends. How do I buy shares of IGM Biosciences? Shares of IGMS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of IGM Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that IGM Biosciences investors own include Pfizer (PFE), Tesla (TSLA), AbbVie (ABBV), ImmunoGen (IMGN), Plug Power (PLUG), Atreca (BCEL) and Carnival Co. & (CCL). This page (NASDAQ:IGMS) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredThese 5 stocks could soar after November 4thHow to Trade this Crazy Election Year? Simple – Just Focus on These 5 stocks… Now available – a free report...StockEarnings | SponsoredKamala’s Dirty Election Move… RevealedAccording to former advisor to the CIA, the Pentagon and the White House Jim Rickards… Kamala and her puppe...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding IGM Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share IGM Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free IGMS Stock Alerts